Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.3 HKD | -2.99% | +2.36% | -10.96% |
04-03 | Ascletis Discontinues Trials of FXR Agonist for Biliary Cholangitis, NASH and Hepatitis B Virus | MT |
04-03 | Ascletis Pharma Inc. Announces Strategic Decisions on FXR Agonist ASC42 | CI |
Sales 2023 | 56.6M 7.81M 61.14M 623M | Sales 2024 * | - | Capitalization | 1.26B 173M 1.36B 13.84B |
---|---|---|---|---|---|
Net income 2023 | -145M -20.02M -157M -1.6B | Net income 2024 * | -219M -30.23M -237M -2.41B | EV / Sales 2023 | -15.6 x |
Net cash position 2023 | 2.27B 313M 2.45B 24.96B | Net cash position 2024 * | 2B 276M 2.16B 22.03B | EV / Sales 2024 * | - |
P/E ratio 2023 |
-9.85
x | P/E ratio 2024 * |
-6.12
x | Employees | 219 |
Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 28.28% |
1 day | -2.99% | ||
1 week | +2.36% | ||
Current month | -9.09% | ||
1 month | -5.11% | ||
3 months | -22.62% | ||
6 months | -30.85% | ||
Current year | -10.96% |
Managers | Title | Age | Since |
---|---|---|---|
Jinzi Wu
CEO | Chief Executive Officer | 61 | - |
Yan Yuemei
CTO | Chief Tech/Sci/R&D Officer | - | - |
Handan He
CTO | Chief Tech/Sci/R&D Officer | - | 06/10/19 |
Members of the board | Title | Age | Since |
---|---|---|---|
Jinzi Wu
CEO | Chief Executive Officer | 61 | - |
Jiong Gu
BRD | Director/Board Member | 51 | 31/03/18 |
Chief Operating Officer | 50 | 12/03/19 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.78% | 4 M€ | -27.92% | ||
0.00% | 34 M€ | +2.14% | - |
Date | Price | Change | Volume |
---|---|---|---|
29/04/24 | 1.3 | -2.99% | 1 494 888 |
26/04/24 | 1.34 | -1.47% | 1,498,000 |
25/04/24 | 1.36 | +3.82% | 456,000 |
24/04/24 | 1.31 | +3.15% | 408,000 |
23/04/24 | 1.27 | 0.00% | 365,000 |
Delayed Quote Hong Kong S.E., April 29, 2024 at 07:02 am
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-10.96% | 173M | |
-4.06% | 86.13B | |
+1.32% | 39.82B | |
-19.27% | 30.42B | |
+57.86% | 25.23B | |
-16.09% | 15.36B | |
-9.14% | 11.95B | |
-17.69% | 11.6B | |
-43.00% | 11.51B | |
+5.24% | 8.71B |
- Stock Market
- Equities
- 1672 Stock